Chengbin Wu Ph.D
Founder and CEO, EpimAb
Chengbin Wu, Ph.D., Founder and Chief Executive Officer of EpimAb
Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics. Until end of April 2016 he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Previously he was the Senior VP Biologics at Shanghai ChemPartner, where he established comprehensive biologics R&D capabilities.
Before that he was a Volwiler Associate Fellow at Abbott laboratories, USA. Dr. Wu has extensive experience in engineering and development of therapeutic monoclonal antibodies. He is also the primary inventor of the DVD-Ig technology, a new bi-specific antibody platform for developing next generation biologics therapies. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral training at Harvard Medical School.